Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline and Unigene to collaborate on new osteoporosis drug

GlaxoSmithKline and Unigene to collaborate on new osteoporosis drug

10th August 2011

GlaxoSmithKline has entered into a new agreement with Unigene on the development of a new osteoporosis drug that is set to enter phase III testing.

The development services and clinical supply agreement will see Unigene receive $2.2 million (1.4 million pounds) to undertake production activities for the active pharmaceutical ingredient and finished drug product.

Unigene and GlaxoSmithKline have been collaborating since 2010 on the creation of the parathyroid hormone (PTH) analogue, an orally-administered therapy that is intended for use among postmenopausal women.

Currently, the drug is undergoing phase II trials, with the new deal having been agreed in anticipation of GlaxoSmithKline's decision to take the product to the next stage of development.

Ashleigh Palmer, president and chief executive officer of Unigene, said: "We have made tremendous progress with our phase II programme since the beginning of the year and are thrilled to be working closely with GlaxoSmithKline on the most advanced oral PTH in development."

According to GlaxoSmithKline's most recent financial report, the company saw underlying sales growth of five percent in the second quarter of 2011.ADNFCR-8000103-ID-800695087-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.